Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease

Bibliography

• SHFox, RKatzenschlager, SYLim, et al. The Movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• SFahn, DOakes, IShoulson, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351(24):2498-508
   PubMed Web of Science ®Google Scholar
• CWOlanow, JAObeso, FStocchi. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006;5(8):677-87
   PubMed Web of Science ®Google Scholar
• DDeleu, MGNorthway, YHanssens. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002;41(4):261-309
   PubMed Web of Science ®Google Scholar
• TNagatsua, MSawadab. L-dopa therapy for Parkinson’s disease: past, present, and future. Parkinsonism Relat Disord 2009;15(Suppl 1):S3-8
   PubMedGoogle Scholar
• PALeWitt, MVNelson, RCBerchou, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(11 Suppl 2):45-53; discussion 59
   PubMed Web of Science ®Google Scholar
• WCKoller, JTHutton, ETolosa, RCapilldeo. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53(5):1012-19
   PubMed Web of Science ®Google Scholar
• WHPoewe, GDeuschl, AGordin, et al. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105(4):245-55
   PubMed Web of Science ®Google Scholar
• UKRinne, JPLarsen, ASiden, JWorm-Petersen. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51(5):1309-14
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997;42(5):747-55
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• ORascol, DJBrooks, EMelamed, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• RBDeweyJr, JTHutton, PALeWitt, SAFactor. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58(9):1385-92
   PubMed Web of Science ®Google Scholar
• KPietz, PHagell, POdin. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65(5):709-16
   PubMed Web of Science ®Google Scholar
• RPahwa, SAFactor, KELyons, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):983-95
   PubMed Web of Science ®Google Scholar
• RPahwa, MAStacy, SAFactor, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007;68(14):1108-15
   PubMed Web of Science ®Google Scholar
• CWOlanow, KKieburtz, POdin, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13(2):141-9
   PubMed Web of Science ®Google Scholar
• WHJost. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf 2014;13(4):447-58
   PubMed Web of Science ®Google Scholar
• WOndo. IPX066, a mixed immediate/sustained-release levodopa preparation for Parkinson’s disease. Expert Opin Pharmacother 2014;15(14):2081-5
   PubMed Web of Science ®Google Scholar
• RPahwa, KELyons, RAHauser, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord 2014;20(2):142-8
   PubMed Web of Science ®Google Scholar
• RAHauser, AHsu, SKell, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12(4):346-56
   PubMed Web of Science ®Google Scholar
• RAHauser, ALEllenbogen, LVMetman, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov Disord 2011;26(12):2246-52
   PubMed Web of Science ®Google Scholar
• FStocchi, AHsu, SKhanna, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord 2014;20(12):1335-40
   PubMed Web of Science ®Google Scholar
• PNausieda, MRudzinska, SKell, et al. IPX066 Extended-release carbidopa-levodopa capsules in patients with early Parkinson’s disease. AAN 2013;80:P01.064
   Google Scholar
• AEllenbogen, PNauseida, EPourcher, et al. Long-term safety of IPX066 extended-release carbidopa-levodopa capsules in patients with motor fluctuations in advanced Parkinson’s disease. AAN 2013;80:P01.065
   Google Scholar
• SKell, MO’Connell, DHsu, et al. The effects of gender on adverse event reporting in Parkinson’s disease patients treated with IPX066 extended-release carbidopa-levodopa capsules. Mov Disord 2013;28(Suppl 1):P414
   Google Scholar
• SKell, MO’Connell, DHsu, et al. The effects of weight on adverse event reporting in Parkinson’s disease patients treated with IPX066 extended-release carbidopa-levodopa capsules. Mov Disord 2013;28(Suppl 1):P410
   Google Scholar
• SKell, MO’Connell, DHsu, et al. The effects of age on adverse event reporting in Parkinson’s disease patients treated with IPX066 extended-release carbidopa-levodopa capsules. J Parkinson’s Dis 2013;3(Suppl 1):P12.18
   Google Scholar
• KKompoliti, CHAdler, RRaman, et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002;58(9):1418-22
   PubMed Web of Science ®Google Scholar
• DNyholm, EKarlsson, MLundberg, HAskmark. Large differences in levodopa dose requirement in Parkinson’s disease: men use higher doses than women. Euro J Neurol 2010;17(2):260-6
   PubMed Web of Science ®Google Scholar
• FLaliberte, BKBookhart, WWNelson, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013;6(3):213-24
   PubMedGoogle Scholar